Read by QxMD icon Read

Cellular Oncology (Dordrecht)

Rosario Castro-Oropeza, Jorge Melendez-Zajgla, Vilma Maldonado, Karla Vazquez-Santillan
BACKGROUND: Tumors contain a functional subpopulation of cells that exhibit stem cell properties. These cells, named cancer stem cells (CSCs), play significant roles in the initiation and progression of cancer. Long non-coding RNAs (lncRNAs) can act at the transcriptional, posttranscriptional and translational level. As such, they may be involved in various biological processes such as DNA damage repair, inflammation, metabolism, cell survival, cell signaling, cell growth and differentiation...
September 14, 2018: Cellular Oncology (Dordrecht)
Rajesh C Rao, May P Chan, Chris A Andrews, Alon Kahana
BACKGROUND: Advanced basal cell carcinomas (BCCs) suffer from a scarcity of effective treatment options. Previously, we found that the targetable histone methyltransferase EZH2 was upregulated in aggressive BCC subtypes, suggesting that epigenetics may play a role in BCC progression. The purpose of this study was to determine whether EZH2-associated proteins and marks may be employed for the stratification of BCC histologic subtypes. METHODS: Sixty-two specimens (from 61 patients), representing more or less aggressive BCC histologic subtypes and matching non-malignant epidermal cells, were included in this study...
September 13, 2018: Cellular Oncology (Dordrecht)
Jelena Marjanovic Vicentic, Danijela Drakulic, Idoia Garcia, Vladanka Vukovic, Paula Aldaz, Nela Puskas, Igor Nikolic, Goran Tasic, Savo Raicevic, Laura Garros-Regulez, Nicolas Sampron, Michael J Atkinson, Natasa Anastasov, Ander Matheu, Milena Stevanovic
PURPOSE: Glioblastoma is the most common and lethal adult brain tumor. Despite current therapeutic strategies, including surgery, radiation and chemotherapy, the median survival of glioblastoma patients is 15 months. The development of this tumor depends on a sub-population of glioblastoma stem cells governing tumor propagation and therapy resistance. SOX3 plays a role in both normal neural development and carcinogenesis. However, little is known about its role in glioblastoma. Thus, the aim of this work was to elucidate the role of SOX3 in glioblastoma...
September 12, 2018: Cellular Oncology (Dordrecht)
Martina Mikulandra, Antonio Kobescak, Benjamin Verillaud, Pierre Busson, Tanja Matijevic Glavan
PURPOSE: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers. Concurrent radio-chemotherapy is the standard of care for advanced tumors. However, there is a need for more efficient regimens with less side effects resulting from high doses. Therefore, we set out to explore the therapeutic potential of ternary combinations by bringing together irradiation, cis-platinum and a TLR3 agonist, poly(I:C), with the aim to reduce the dosage of each treatment. This approach is based on our previous work, which revealed a selective cytotoxic effect of TLR3 agonists against malignant cells when combined with other anti-neoplastic agents...
September 4, 2018: Cellular Oncology (Dordrecht)
Alessandro Del Gobbo, Nicola Fusco, Marco Barella, Giulia Ercoli, Amedeo Sciarra, Alessandro Palleschi, Fabio Pagni, Caterina Marchiò, Mauro Papotti, Stefano Ferrero
PURPOSE: Neuroendocrine tumors of the lung (LNETs) encompass a heterogeneous group of lesions, including tumors with no or low metastatic potential, such as typical (TCs) and atypical (ACs) carcinoids, and highly aggressive neuroendocrine carcinomas. To date, only a few biomarkers with prognostic impact have been identified in LNETs. Previous experimental studies have suggested that the cytokine CXCL12 might have a role in stratifying the outcome of lung cancer as well as LNET patients...
September 4, 2018: Cellular Oncology (Dordrecht)
Claudia Busonero, Stefano Leone, Fabrizio Bianchi, Filippo Acconcia
PURPOSE: Most breast cancers (BCs) express estrogen receptor α (ERα) and are treated with the endocrine therapy (ET) drugs 4OH-tamoxifen (Tam) and fulvestrant (ICI 182,780; ICI). Unfortunately, a high fraction of ET treated women relapses and becomes resistant to ET. Therefore, additional anti-BC drugs are needed. Recently, we proposed that the identification of novel anti-BC drugs can be achieved using modulation of the intracellular ERα content in BC cells as a pharmacological target...
September 4, 2018: Cellular Oncology (Dordrecht)
Eun-Hui Jeong, Tae-Gul Lee, Yun Jung Ko, Seo Yun Kim, Hye-Ryoun Kim, Hyunggee Kim, Cheol Hyeon Kim
BACKGROUND: Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of non-small cell lung cancer (NSCLC). Although the discovery of driver mutations and their targeted drugs has remarkably improved the treatment outcomes for lung adenocarcinoma, currently no such molecular target is clinically available for SqCLC. The CDKN2A locus at 9p21 encodes two alternatively spliced proteins, p16INK4a (p16) and p14ARF (p14), which function as cell cycle inhibitors. The Cancer Genome Atlas (TCGA) project revealed that CDKN2A is inactivated in 72% of SqCLC cases...
September 3, 2018: Cellular Oncology (Dordrecht)
Xuan Sun, Robert C G Martin, Qianqian Zheng, Russell Farmer, Harshul Pandit, Xuanyi Li, Kevin Jacob, Jian Suo, Yan Li
BACKGROUND: With a less than 5% overall survival rate, esophageal adenocarcinoma (EAC) is one of the leading causes of death in the United States. Epithelial cell adhesion molecule (EpCAM) is a cancer stem cell (CSC) marker that is expressed in various epithelial carcinomas, including EAC. Accumulating evidence indicates that CSC subpopulations can initiate cancer development and, in addition, drive metastasis, recurrence and drug resistance. It has also been reported that EpCAM up-regulation in EAC may lead to an aggressive behavior and, thus, an adverse clinical outcome...
August 16, 2018: Cellular Oncology (Dordrecht)
Lisett Contreras, Ruben I Calderon, Armando Varela-Ramirez, Hong-Yu Zhang, Yuan Quan, Umashankar Das, Jonathan R Dimmock, Rachid Skouta, Renato J Aguilera
PURPOSE: Previously, compounds containing a piperidone structure have been shown to be highly cytotoxic to cancer cells. Recently, we found that the piperidone compound P2 exhibits a potent anti-neoplastic activity against human breast cancer-derived cells. Here, we aimed to evaluate two piperidone compounds, P1 and P2, for their potential anti-neoplastic activity against human leukemia/lymphoma-derived cells. METHODS: Cytotoxicity and apoptosis induction were evaluated using MTS, annexin V-FITC/PI and mitochondrial membrane potential polychromatic assays to confirm the mode of action of the piperidone compounds...
August 7, 2018: Cellular Oncology (Dordrecht)
Prateek Sharma, Sanjeev Kumar
PURPOSE: Despite a growing body of evidence indicating a potential efficacy of the anti-diabetic metformin as anti-cancer agent, the exact mechanism underlying this efficacy has remained largely unknown. Here, we aimed at assessing putative mechanisms associated with the ability of metformin to reduce the proliferation and migration of breast cancer cells. METHODS: A battery of in vitro assays including MTT, colony formation, NBT and scratch wound healing assays were performed to assess the viability, proliferation, anti-oxidative potential and migration of breast cancer-derived MCF-7, MDA-MB-231 and T47D cells, respectively...
August 7, 2018: Cellular Oncology (Dordrecht)
Marijana Kovačić, Olivera Mitrović-Ajtić, Bojana Beleslin-Čokić, Dragoslava Djikić, Tijana Subotički, Miloš Diklić, Danijela Leković, Mirjana Gotić, Pascal Mossuz, Vladan P Čokić
PURPOSE: Previously, the family of S100A proteins has been found to be associated with inflammation and myelopoiesis and to be able to induce or support myeloproliferation during chronic inflammation. Here, we studied the inflammatory myeloid-related proteins S100A4, S100A8, S100A9 and S100A12 in myeloproliferative neoplasms (MPNs) in order to assess the involvement of chronic inflammation in the pathogenesis of MPN. METHODS: We analyzed the S100A4, S100A8, S100A9 and S100A12 mRNA and protein levels in the bone marrow and circulation of 140 patients with MPN and 15 healthy controls using Western blotting, microarray-based mRNA expression profiling and ELISA assays, respectively...
June 26, 2018: Cellular Oncology (Dordrecht)
Xin Chen, Arnaud J Legrand, Siobhan Cunniffe, Samuel Hume, Mattia Poletto, Bruno Vaz, Kristijan Ramadan, Dengfu Yao, Grigory L Dianov
BACKGROUND: To deliver efficacious personalised cancer treatment, it is essential to characterise the cellular metabolism as well as the genetic stability of individual tumours. In this study, we describe a new axis between DNA repair and detoxification of aldehyde derivatives with important implications for patient prognosis and treatment. METHODS: Western blot and qPCR analyses were performed in relevant non-transformed and cancer cell lines from lung and liver tissue origin in combination with bioinformatics data mining of The Cancer Genome Atlas database from lung and hepatocellular cancer patients...
October 2018: Cellular Oncology (Dordrecht)
Suhrid Banskota, Sadan Dahal, Eunju Kwon, Dong Young Kim, Jung-Ae Kim
In the original version of above mentioned article an error occurred in Fig. 2. Panel g and panel h are included in the figure legend, but have not been published in the figure.
October 2018: Cellular Oncology (Dordrecht)
Kaumudi Bhawe, Deodutta Roy
BACKGROUND: Nuclear respiratory factor 1 (NRF1), historically perceived as a protein regulating genes controlling mitochondrial biogenesis, is now widely recognized as a multifunctional protein and as a key player in the transcriptional modulation of genes implicated in various cellular functions. Here, we present emerging data supporting novel roles of NRF1 in cancer development and progression through its interplay with the transcription factors E2F4 and MYC. To identify common human NRF1, E2F4 and MYC target genes, we analyzed the Encyclopedia of DNA Elements (ENCODE) NRF1 ChIP-Seq data...
October 2018: Cellular Oncology (Dordrecht)
Carsten Pelz, Sonja Häckel, Geo Semini, Sandra Schrötter, Willem Bintig, Sebastian Stricker, Gudrun Mrawietz, Andreas Klein, Lothar Lucka, Vadim Shmanai, Britta Eickholt, Annette Hildmann, Kerstin Danker
PURPOSE: Previous studies have identified alkyl-phospholipids as promising compounds for cancer therapy by targeting constituents of the cell membrane and different signaling pathways. We previously showed that the alkylphospholipid Inositol-C2-PAF inhibits the proliferation and migration of immortalized keratinocytes and the squamous carcinoma-derived cell line SCC-25. Here, we investigated the effect of this compound on growth and motility as well as its mode of action in mammary carcinoma-derived cell lines...
October 2018: Cellular Oncology (Dordrecht)
Aleksandra M Dudek, Sita H Vermeulen, Dimitar Kolev, Anne J Grotenhuis, Lambertus A L M Kiemeney, Gerald W Verhaegh
PURPOSE: Genome-wide association studies (GWAS) have led to the identification of a bladder cancer susceptibility variant (rs710521) in a non-coding intergenic region between the TP63 and LEPREL1 genes on chromosome 3q28, suggesting a role in the transcriptional regulation of these genes. In this study, we aimed to functionally characterize the 3q28 bladder cancer risk locus. METHODS: Fine-mapping was performed by focusing on the region surrounding rs710521, and variants were prioritized for further experiments using ENCODE regulatory data...
October 2018: Cellular Oncology (Dordrecht)
Linus Angenendt, Jan-Henrik Mikesch, Dennis Görlich, Alina Busch, Irina Arnhold, Claudia Rudack, Wolfgang Hartmann, Eva Wardelmann, Wolfgang E Berdel, Markus Stenner, Christoph Schliemann, Inga Grünewald
PURPOSE: Collagen Type VI (COLVI) is an extracellular matrix protein that is upregulated in various solid tumours during tumour progression and has been shown to stimulate proliferation, suppress apoptosis and promote invasion and metastasis. It has also been described as a mediator of chemotherapy resistance and as a therapeutic target in preclinical cancer models. Here, we aimed to analyse the prognostic role of COLVI in salivary gland cancer (SGC). METHODS: Stromal COLVI protein expression was assessed in primary SGC specimens of 91 patients using immunohistochemistry (IHC)...
October 2018: Cellular Oncology (Dordrecht)
Wuyi Wang, Lin Wan, Shiyang Wu, Jianguo Yang, Yang Zhou, Fang Liu, Zhengzheng Wu, Yong Cheng
PURPOSE: The presence of circulating tumor cells (CTCs) has been found to correlate with colorectal cancer (CRC) prognosis, whereas epithelial-mesenchymal transition (EMT) in CTCs has been found to be associated with CRC metastasis. LGR5 is a known target of Wnt signaling and plays an important role in CRC development. The aim of this study was to assess the clinical relevance of EMT and LGR5 expression in CTCs from CRC patients. METHODS: Sixty-six CRC patients were included in this study...
October 2018: Cellular Oncology (Dordrecht)
Dominik Kraus, Jan Reckenbeil, Nadine Veit, Stefan Kuerpig, Michael Meisenheimer, Imke Beier, Helmut Stark, Jochen Winter, Rainer Probstmeier
BACKGROUND: Targeting glucose metabolism is a promising way to interfere with tumor cell proliferation and survival. However, controversy exists about the specificity of some glucose metabolism targeting anticancer drugs. Especially the potency of STF-31 has been debated. Here, we aimed to assess the impact of the glucose transporter (GLUT) inhibitors fasentin and WZB117, and the nicotinamide phosphoribosyltransferase (NAMPT) inhibitors GMX1778 and STF-31 on tumor cell proliferation and survival, as well as on glucose uptake...
October 2018: Cellular Oncology (Dordrecht)
Suhrid Banskota, Sadan Dahal, Eunju Kwon, Dong Young Kim, Jung-Ae Kim
PURPOSE: Over half of the colon cancer patients suffer from cancer-related events, mainly metastasis. Loss of β-catenin activity has previously been found to facilitate cancer cell dissociation and migration. Here, we aimed to investigate whether epigenetic silencing of β-catenin induces human colon cancer cell migration and/or invasion. METHODS: HCT-116, Caco-2, HT-29 and SW620 cell migration and invasion capacities were assessed using scratch wound healing and Matrigel invasion assays, respectively...
October 2018: Cellular Oncology (Dordrecht)
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"